文献速递肾移植

达雷妥尤单抗治疗慢性活动性抗体介导的肾移植排斥反应

Anti-CD38 Daratumumab Treatment of Chronic Active Antibody-Mediated Kidney Allograft Rejection.
PubMed 文献 · Kidney Int Rep · 2025-07-15

本研究回顾性分析了16例肾移植术后慢性活动性抗体介导排斥反应患者,接受皮下达雷妥尤单抗1800mg每周一次共4周,后续每季度3次治疗。治疗后10个月,13例微血管炎症评分改善,分子ABMR评分中位下降74%,8例完全分子缓解,eGFR稳定,dd-cfDNA中位下降85%,2例DSA转阴。结论提示达雷妥尤单抗可能有效,需随机试验验证。

要点

  • 皮下达雷妥尤单抗可能改善慢性活动性ABMR的组织学和分子学指标。
  • dd-cfDNA显著下降,或可用于监测复发。
  • 治疗耐受性良好,无重大不良事件。

核心结论

  • 皮下达雷妥尤单抗可能有效治疗肾移植后慢性活动性ABMR,需更大规模随机试验验证。

研究设计与样本

  • 回顾性图表审查,纳入16例肾移植术后>6个月诊断为cABMR的患者,接受皮下达雷妥尤单抗1800mg每周一次共4周,后续每季度3次。

主要发现

  • 治疗后10个月,16例中13例微血管炎症评分改善,分子ABMR评分中位下降74%,8例完全分子缓解。
  • eGFR稳定,UACR在16例中11例改善,dd-cfDNA中位下降85%。
  • 12例既往DSA阳性者中2例转阴,2例基于dd-cfDNA复发后再次治疗稳定/改善。
  • 无重大不良事件发生。

临床怎么用

  • 达雷妥尤单抗可作为cABMR的治疗选择,dd-cfDNA可用于监测复发。

局限性

  • 回顾性设计,样本量小(16例),缺乏对照组,需随机试验确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Chronic active (c) antibody-mediated rejection (ABMR) (cABMR) remains the leading cause of graft loss in kidney transplant recipients (KTRs). The efficacy of subcutaneous daratumumab, an anti-CD38 monoclonal antibody targeting plasma cells and natural killer (NK) cells, to treat cABMR was studied. METHODS: A retrospective chart review was performed on KTRs with cABMR diagnosed > 6 months after transplantation and treated with a flat dose of subcutaneous daratumumab 1800 mg weekly for 4 weeks followed by 3 quarterly doses. The patients were monitored before and after treatment using estimated glomerular filtration rate (eGFR), urine albumin-to-creatinine ratio (UACR), renal-biopsy, donor-derived cell-free DNA (dd-cfDNA) and donor-specific antibody (DSA) levels. Adverse events were monitored. RESULTS: Sixteen KTR with cABMR (median time from transplantation to treatment: 9 years) were treated with daratumumab. No major adverse events occurred. After 10 months, biopsy histology showed improvement in microvascular inflammation scores in 13 of 16 patients and molecular ABMR scores decreased (median 74% decline), with 8 of 16 patients experiencing complete molecular remission of ABMR. eGFR levels remained stable, UACR improved in 11 of 16 patients and dd-cfDNA significantly decreased (median decrease: 85%). DSA became negative in 2 of 12 previously positive patients. After completion of treatment, patients were monitored quarterly with eGFR, UACR, and dd-cfDNA. Two patients showed recurrence of cABMR based on dd-cfDNA, were retreated, and showed stabilization/improvement. CONCLUSION: Subcutaneous daratumumab may be an effective treatment for cABMR; larger randomized trials are warranted to study its role in the treatment for cABMR in KTRs. dd-cfDNA may be a useful monitoring tool to predict and detect relapses.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Lye WC, Loh HL. Anti-CD38 Daratumumab Treatment of Chronic Active Antibody-Mediated Kidney Allograft Rejection. Kidney Int Rep. 2025. PMID: 41141546. doi:10.1016/j.ekir.2025.07.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。